Somatic cell reprogramming
The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.
1. A method of reprogramming human somatic cells, the method comprising the steps of:
introducing a non-integrating vector encoding Oct-4 and Sox2 and at least one of Nanog and Lin28 operably linked to one or more heterologous promoters into isolated human somatic cells; and
culturing the somatic cells under embryonic stem (ES) cell culture conditions such that pluripotent reprogrammed cells are obtained.
2. The method of claim 1 , wherein the somatic cells are obtained from a post-natal individual.
3. The method of claim 1 , wherein the somatic cells are obtained by in vitro differentiation of a stem cell.
4. The method of claim 1 , wherein the non-integrating vector is an Epstein-Barr virus nuclear antigen (EBNA)-based vector.
5. The method of claim 1 , wherein the reprogrammed cells (i) express a cell marker selected from the group consisting of Oct-4, SSEA3, SSEA4, Tra-1-60 and Tra-1-81; (ii) exhibit morphology characteristic of pluripotent cells; and (iii) form teratomas when introduced into an immunocompromised animal.
6. A method of reprogramming human somatic cells, the method comprising the steps of:
introducing a non-integrating vector encoding Oct-4, Sox2, and at least one of Nanog and Lin28 operably linked to one or more heterologous promoters into isolated human somatic cells; and
culturing the somatic cells under embryonic stem cell culture conditions such that reprogrammed cells having a higher potency level than the somatic cells are obtained.
7. A method of producing an induced pluripotent stem (iPS) cell, comprising the steps of:
introducing one or a plurality of non-integrating vectors into a human somatic cell in vitro, wherein the one or plurality of non-integrating vectors comprise nucleic acid sequences encoding potency-determining factors Oct 4, Sox 2, and at least one of Nanog and Lin28; and
culturing the somatic cell in a medium that supports pluripotent stem cells such that iPS cells are obtained.
8. The method of claim 7 , wherein the one or plurality of non-integrating vectors comprises an IRES coding region.
9. The method of claim 7 , wherein a plurality of non-integrating vectors are introduced into a single somatic cell.
10. The method of claim 6 , wherein the reprogrammed cells are free of any vector component used to introduce the reprogramming factors.
11. The method of claim 7 , wherein the culturing step is performed without selection.
12. The method of claim 7 , wherein the iPS cells do not comprise the one or the plurality of non-integrating vectors.
13. A method of producing an induced pluripotent stem cell, comprising the steps of:
introducing one or more Epstein-Barr virus nuclear antigen (EBNA)-based non-integrating vectors encoding Oct 4, Sox 2, and at least one of Nanog and Lin28 operably linked to one or more heterologous promoters into a human somatic cell in vitro; and
culturing the somatic cell in a medium that supports pluripotent stem cells such that iPS cells are obtained.
14. The method of claim 13 , wherein two or more EBNA-based non-integrating vectors comprising different genes from each other are introduced into the somatic cell.
15. The method of claim 14 , wherein the two or more EBNA-based non-integrating vectors comprising different genes from each other are introduced into the somatic cell concurrently.
16. The method of claim 1 , wherein the plurality of factors are introduced into the somatic cells on one or more EBNA-based non-integrating vectors.
17. The method of claim 6 , wherein the plurality of factors are introduced into the somatic cells on one or more EBNA-based non-integrating vectors.